Что лежит в основе эффективности лечения периндоприлом больных ишемической болезнью сердца – небольшое снижение артериального давления или нечто большее? Итоги и перспективы исследования EUROPA
Аннотация
Об авторе
В. Н. ХирмановРоссия
Список литературы
1. Fox K.M. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators/Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double - blind, placebo - controlled, multicentre trial (the EUROPA study). Lancet 2003; 362 (9386): 782–8.
2. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin - converting - enzyme inhibitor, ramipril, on cardiovascular events in high - risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342 (3): 1451–3.
3. Chobanian A.V, Bakris G.L, Black H.R et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289 (19): 2560–72.
4. European Society of Hypertension-European Society of Cardiology Guidelines Committee/2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21 (6): 1011–53.
5. Benetos A, Thomas F, Bean K.E, Guize L. Why cardiovascular mortality is higher in treated hypertensives versus subjects of the same age, in the general population. J Hypertens 2003; 21 (9): 1635–40.
6. Boutitie F, Gueyffier F, Pocock S et al. INDANA Project Steering Committee. INdividual Data ANalysis of Antihypertensive intervention. J-shaped relationship between blood pressure and mortality in hypertensive patients: new insights from a meta - analysis of individual - patient data. Ann Intern Med 2002; 136 (6): 438–48.
7. Candido R, Jandeleit-Dahm K.A, Cao Z et al. Prevention of accelerated atherosclerosis by angiotensin - converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 2002; 106 (2): 246–53.
8. Cook N.R, Cohen J, Hebert P.R et al. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 1995; 155 (7): 701–9.
9. Mac Mahon S, Peto R, Cutler J et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335 (8692): 765–74.
10. Britten M.B, Zeiher A.M, Schachinger V. Clinical importance of coronary endothelial vasodilator dysfunction and therapeutic options. J Intern Med 1999; 245 (4): 315–27.
11. Brown N.J, Agirbasli M.A, Williams G.H et al. Effect of activation and inhibition of the renin - angiotensin system on plasma PAI-1. Hypertension 1998; 32 (6): 1225–32.
12. Dzau V.J, Bernstein K, Celermajer D et al.
13. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin - converting enzyme inhibitors in humans. Circulation 1997; 95 (5): 1115–8.
14. Lazar H, Lonn E, Luscher T et al. Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. Cardiovasc Drugs Ther 2002; 16 (2): 149–60.
15. Marui N, Offermann M.K, Swerlick R et al. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant - sensitive mechanism in human vascular endothelial cells. J Clin Invest 1993; 92 (4): 1866–74.
16. Matsumoto K, Morishita R, Moriguchi A et al. Inhibition of neointima by angiotensin - converting enzyme inhibitor in porcine coronary artery balloon - injury model. Hypertension 2001; 37 (2): 270–4.
17. Vaughan D.E, Lazos S.A, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: a potential link between the renin - angiotensin system and thrombosis. J Clin Invest 1995; 95 (3): 995–1001.
18. Bartels G.L, Van den Heuvel A.F.M, Van Veldhuisen D.J, Van der Ent M, Remme W.J. Acute anti - ischemic effects of perindoprilat in men with coronary artery disease and their relation with left ventricular function. Am J Cardiol 1999; 83 (3): 332–6.
19. Gomma A.H, Fox K.M, on behalf of the EUROPA Investigators / The EUROPA trial: design, baseline demography and status of the substudies. Cardiovasc Drugs Ther 2001; 15 (2): 169–79.
20. Scientific Committee of the PERTINENT Sub-Study, EUROPA-PERTINENT Investigators/PERTINENT – perindopril - thrombosis, inflammation, endothelial dysfunction and neurohormonal activation trial: a sub - study of the EUROPA study. Cardiovasc Drugs Ther 2003; 17 (1): 83–91.
Рецензия
Для цитирования:
Хирманов В.Н. Что лежит в основе эффективности лечения периндоприлом больных ишемической болезнью сердца – небольшое снижение артериального давления или нечто большее? Итоги и перспективы исследования EUROPA. Системные гипертензии. 2004;(1):34-37.
Послать статью по эл. почте 